ADMA Biologics, Inc. (ADMA) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ADMA Insider Trading Activity
ADMA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $18,228,172 | 11 | 100 |
Related Transactions
| Guiheen Lawrence P. | director | 0 | $0 | 1 | $166,189 | $-166,189 |
| Tade Brad L. | CFO and Treasurer | 0 | $0 | 1 | $317,250 | $-317,250 |
| Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | 0 | $0 | 1 | $408,050 | $-408,050 |
| KWON YOUNG | director | 0 | $0 | 1 | $1.1M | $-1.1M |
| Grossman Jerrold B | director | 0 | $0 | 1 | $2.36M | $-2.36M |
| Grossman Adam S | President,CEO, and Interim CFO | 0 | $0 | 6 | $13.88M | $-13.88M |
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Insider Activity of ADMA Biologics, Inc.
Over the last 12 months, insiders at ADMA Biologics, Inc. have bought $0 and sold $18.23M worth of ADMA Biologics, Inc. stock.
On average, over the past 5 years, insiders at ADMA Biologics, Inc. have bought $349,589 and sold $14.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 130,000 shares for transaction amount of $482,144 was made by Grossman Jerrold B (director) on 2023‑08‑30.
List of Insider Buy and Sell Transactions, ADMA Biologics, Inc.
| 2025-04-15 | Sale | Grossman Adam S | President and CEO | 21,000 0.0103% | $21.46 | $450,660 | -0.34% | |
| 2025-03-19 | Sale | Grossman Adam S | President and CEO | 21,000 0.0082% | $18.92 | $397,320 | -1.36% | |
| 2024-11-22 | Sale | Grossman Adam S | President and CEO | 48,967 0.0205% | $21.10 | $1.03M | -12.65% | |
| 2024-11-22 | Sale | Tade Brad L. | CFO and Treasurer | 15,000 0.0063% | $21.15 | $317,250 | -12.65% | |
| 2024-09-09 | Sale | Guiheen Lawrence P. | director | 9,000 0.0039% | $18.47 | $166,189 | +1.58% | |
| 2024-08-30 | Sale | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | 24,150 0.0101% | $16.90 | $408,050 | +7.51% | |
| 2024-08-29 | Sale | Grossman Jerrold B | director | 136,861 0.0589% | $17.27 | $2.36M | +7.96% | |
| 2024-08-27 | Sale | Grossman Adam S | President and CEO | 389,356 0.1665% | $17.29 | $6.73M | +6.97% | |
| 2024-08-26 | Sale | Grossman Adam S | President and CEO | 236,889 0.103% | $17.69 | $4.19M | +6.30% | |
| 2024-08-23 | Sale | KWON YOUNG | director | 60,000 0.0255% | $18.26 | $1.1M | +0.87% | |
| 2024-06-14 | Sale | Grossman Adam S | President,CEO, and Interim CFO | 100,000 0.044% | $10.72 | $1.07M | +65.29% | |
| 2024-03-19 | Sale | ELMS STEVE | director | 411,829 0.1772% | $6.08 | $2.5M | +161.39% | |
| 2024-03-18 | Sale | ELMS STEVE | director | 49,887 0.0221% | $6.01 | $299,821 | +172.22% | |
| 2024-03-15 | Sale | ELMS STEVE | director | 183,008 0.0805% | $6.01 | $1.1M | +169.78% | |
| 2024-03-14 | Sale | ELMS STEVE | director | 448,276 0.1906% | $6.05 | $2.71M | +168.36% | |
| 2024-03-13 | Sale | ELMS STEVE | director | 407,000 0.1776% | $6.21 | $2.53M | +157.75% | |
| 2023-08-30 | Grossman Jerrold B | director | 130,000 0.0588% | $3.71 | $482,144 | +53.55% | ||
| 2023-08-24 | KWON YOUNG | director | 25,000 0.0108% | $3.90 | $97,500 | +39.53% | ||
| 2023-08-22 | Sale | Fong Bryant | director | 1.43M 0.637% | $3.87 | $5.54M | +38.76% | |
| 2023-08-18 | Sale | Grossman Adam S | President and CEO | 250,000 0.1139% | $4.15 | $1.04M | +30.00% |
Insider Historical Profitability
| Grossman Adam S | President and CEO | 2055850 0.8611% | $40.87M | 37 | 9 | <0.0001% |
| Grossman Jerrold B | director | 467305 0.1957% | $9.29M | 17 | 1 | <0.0001% |
| Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | 449088 0.1881% | $8.93M | 0 | 1 | |
| KWON YOUNG | director | 241441 0.1011% | $4.8M | 2 | 1 | +48.43% |
| Tade Brad L. | CFO and Treasurer | 199433 0.0835% | $3.96M | 0 | 1 | |
| Guiheen Lawrence P. | director | 153941 0.0645% | $3.06M | 5 | 1 | <0.0001% |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 13262375 5.5553% | $263.66M | 3 | 9 | <0.0001% |
| Biotest Divestiture Trust | 10 percent owner | 4295580 1.7993% | $85.4M | 0 | 2 | |
| Aisling Capital II LP | 10 percent owner | 3620143 1.5164% | $71.97M | 1 | 0 | |
| ELMS STEVE | director | 2115671 0.8862% | $42.06M | 0 | 5 | |
| Burrill Capital Fund IV, L.P. | 10 percent owner | 1433304 0.6004% | $28.49M | 1 | 0 | |
| LENZ BRIAN | EVP, CFO | 782013 0.3276% | $15.55M | 15 | 2 | +5.59% |
| Mond James | EVP, CSO and CMO | 73174 0.0307% | $1.45M | 8 | 0 | +2.83% |
| RICHMAN ERIC I | director | 36530 0.0153% | $726,216.40 | 3 | 0 | +39.74% |
| DEMSKI MARTHA J | director | 4200 0.0018% | $83,496.00 | 2 | 0 | <0.0001% |
| Fong Bryant | director | 0 0% | $0 | 0 | 1 | |
| Biotest AG | 10 percent owner | 0 0% | $0 | 1 | 1 | +103.33% |
Historical Insider Profitability vs. Competitors
ADMA Biologics, Inc. (ADMA) | $52,263,649 | 70 | 1.18% | $4.75B |
$108,876,545 | 67 | 72.81% | $6.19B | |
$42,463,802 | 57 | 17.85% | $3.56B | |
$88,307,390 | 38 | -1.70% | $6.34B | |
$62,927,079 | 29 | 14.02% | $3.75B | |
$415,105,240 | 19 | -14.04% | $6.32B | |
$11,859,102 | 17 | 18.62% | $3.66B | |
$103,944,213 | 17 | 5.95% | $3.61B | |
$1,279,017 | 16 | 51.12% | $5.2B | |
$57,686,748 | 13 | 21.11% | $3.68B | |
$2,477,801 | 11 | 4.98% | $5.09B | |
$11,898,979 | 10 | 54.58% | $3.89B | |
$103,741 | 9 | 49.60% | $5.18B | |
$2,246,813 | 6 | 70.15% | $5.3B | |
$14,400,000 | 5 | 41.34% | $3.48B | |
$105,414,951 | 5 | 10.07% | $5.13B | |
$41,376,000 | 4 | -12.07% | $3.88B | |
$36,900,000 | 3 | -9.12% | $3.6B | |
$6,678,053 | 3 | 30.56% | $5.75B |
ADMA Institutional Investors: Active Positions
| Increased Positions | 196 | +59.76% | 20M | +9.59% |
| Decreased Positions | 150 | -45.73% | 32M | -15.02% |
| New Positions | 71 | New | 8M | New |
| Sold Out Positions | 36 | Sold Out | 4M | Sold Out |
| Total Postitions | 374 | +14.02% | 201M | -5.43% |
ADMA Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $876,974.00 | 15.6% | 37.29M | -863,629 | -2.26% | 2025-03-31 |
| Vanguard Group Inc | $428,036.00 | 7.62% | 18.2M | +80,302 | +0.44% | 2024-12-31 |
| State Street Corp | $349,760.00 | 6.22% | 14.87M | +2M | +14.35% | 2024-12-31 |
| Invesco Ltd. | $265,688.00 | 4.73% | 11.3M | -1M | -10.49% | 2024-12-31 |
| Morgan Stanley | $130,168.00 | 2.32% | 5.53M | -3M | -35.64% | 2024-12-31 |
| Geode Capital Management, Llc | $127,770.00 | 2.27% | 5.43M | +50,399 | +0.94% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $109,799.00 | 1.95% | 4.67M | +643,661 | +15.99% | 2024-12-31 |
| Nuveen Asset Management, Llc | $107,070.00 | 1.91% | 4.55M | -2M | -30.79% | 2024-12-31 |
| Deutsche Bank Ag | $91,157.00 | 1.62% | 3.88M | -256,311 | -6.2% | 2024-12-31 |
| American Century Companies Inc | $88,754.00 | 1.58% | 3.77M | -436,091 | -10.36% | 2024-12-31 |